Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)
222090
Phase 3 small_molecule active
Quick answer
Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted) for Respiratory Syncytial Virus Infections is a Phase 3 program (small_molecule) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline Biologicals S.A.
- Indication
- Respiratory Syncytial Virus Infections
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active